BIOMAT Database Logo BIOMAT Database Logo

Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. 2013

Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Department of Molecular Medicine, Padua General Hospital, University of Padua School of Medicine, Padua, Italy. davide.abate@unipd.it

Assessing cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) represents an appealing strategy for identifying transplant recipients at risk of infection. In this study, we compared two gamma interferon-releasing assays (IGRAs), Quantiferon-CMV and CMV enzyme-linked immunosorbent spot (ELISPOT), to determine the ability of each test to predict protective CMV-specific T-cell responses. Two hundred twenty-one Quantiferon-CMV and ELISPOT tests were conducted on 120 adult kidney transplant recipients (KTRs), including 100 CMV-seropositive transplant recipients (R+) and 20 CMV-seronegative transplant recipients of a CMV-positive donor (D+/R-). As a control cohort, 39 healthy adult subjects (including 33 CMV-seropositive and 6 CMV-seronegative subjects) were enrolled. CMV IgG serology was used as a reference for both tests. In the CMV-seropositive individuals, the ELISPOT and Quantiferon-CMV assays provided 46% concordance with the serology, 12% discordance, 18% disagreement between ELISPOT or Quantiferon-CMV and the serology, and 24% gray areas when one or both tests resulted in weak positives. None of the CMV-seronegative subjects showed detectable responses in the ELISPOT or the Quantiferon-CMV test. In transplant recipients, both the ELISPOT and Quantiferon-CMV assays positively correlated with each other and negatively correlated with CMV DNAemia in a significant way (P<0.05). During the antiviral prophylaxis, all 20 D+/R- KTRs we examined displayed undetectable Quantiferon-CMV and ELISPOT results, and there was no evidence of CMV seroconversion. The receiving operator curve (ROC) statistical analysis revealed similar specificities and sensitivities in predicting detectable viremia (areas under the curve [AUC], 0.66 and 0.62 for Quantiferon-CMV and ELISPOT, respectively). ELISPOT and Quantiferon-CMV values of >150 spots/200,000 peripheral blood mononuclear cells (PBMCs) and >1 to 6 IU gamma interferon (IFN-γ) were associated with protection from CMV infection (odds ratios [OR], 5 and 8.75, respectively). In transplant recipients, the two tests displayed similar abilities for predicting CMV infection. Both the ELISPOT and Quantiferon-CMV assays require several ameliorations to avoid false-negative results.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D003951 Diagnostic Errors Incorrect or incomplete diagnoses following clinical or technical diagnostic procedures. Diagnostic Blind Spots,Errors, Diagnostic,Misdiagnosis,Blind Spot, Diagnostic,Blind Spots, Diagnostic,Diagnostic Blind Spot,Diagnostic Error,Error, Diagnostic,Misdiagnoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Utility of the Interferon-Gamma Enzyme-Linked Immunosorbent Spot Assay to Predict Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.
January 2023, Transplant international : official journal of the European Society for Organ Transplantation,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients.
July 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients.
October 2017, Immune network,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
January 2017, PloS one,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
August 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection.
August 2022, Archivos de bronconeumologia,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Latex agglutination and enzyme-linked immunosorbent assays for cytomegalovirus serologic screening of transplant donors and recipients.
October 1988, Journal of clinical microbiology,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
January 2021, PloS one,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
January 2023, PloS one,
Davide Abate, and Alda Saldan, and Carlo Mengoli, and Marta Fiscon, and Cristina Silvestre, and Loredana Fallico, and Marta Peracchi, and Lucrezia Furian, and Riccardo Cusinato, and Luciana Bonfante, and Barbara Rossi, and Francesco Marchini, and Dino Sgarabotto, and Paolo Rigotti, and Giorgio Palù
Monitoring of cellular immunity by interferon-gamma enzyme-linked immunosorbent spot assay in kidney allograft recipients: preliminary results of a longitudinal study.
May 2006, Transplantation proceedings,
Copied contents to your clipboard!